Latest news & events

Tuesday, February 20, 2018

Business Update Conference Call

NOV 15, 2016

Business Update Conference Call

Jan 12, 2018

DelMar Regains NASDAQ Compliance

Jan 01, 2018

Departure of Directors or Certain Officers

View all news


VAL-083, our first product candidate, represents a "first-in-class" small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.

Learn more about VAL-083


Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.

Learn more about DelMar


Our drug discovery research focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications.

Learn more about our drug development pipeline